176505-53-6

Upstream product

• 37526-89-9 benzyl 3-methylbut-2-enoate 
• 100-39-0 benzyl bromide 
• 541-47-9 3-Methylbutenoic acid 

Downstream Products

• 176505-51-4 (S)-5,5-Dimethyl-2,2-dioxo-2λ⁶-[1,3,2]dioxathiolane-4-carboxylic acid benzyl ester 
• 176505-54-7 (R)-2-Azido-3-hydroxy-3-methyl-butyric acid benzyl ester 
• 2280-48-0 (R)-(-)-β-hydroxyvaline 
• 1025811-20-4 (S)-5,5-Dimethyl-2-oxo-2λ⁴-[1,3,2]dioxathiolane-4-carboxylic acid benzyl ester 
• 500734-31-6 2-(1-tert-butoxycarbonylamino-2-methyl-propyl)-thiazole-4-carboxylic acid 1-(1-{1-[1-(allyloxycarbonylmethyl-carbamoyl)-2-(tert-butyl-diphenyl-silanyloxy)-ethylcarbamoyl]-2-hydroxy-2-methyl-propoxycarbonyl}-1-methyl-ethyl)-5,5-dichloro-hexyl ester 
• 500734-32-7 [2S,8R,11S,15S]-8-(tert-butyldiphenylsilanyloxymethyl)-15-(4,4-dichloropentyl)-11-(1-hydroxy-1-methyl-ethyl)-2-isopropyl-14,14-dimethyl-12,16-dioxa-20-thia-3,6,9,21-tetraaza-bicyclo[16.2.1]heneicosa-1⁽²¹⁾,18-diene-4,7,10,13,17-pentaone 

Relevant academic research and scientific papers

NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND PHARMACEUTICAL APPLICATION THEREOF

It is intended to provide a compound represented by the general formula (I): (I) (wherein all the symbols are as defined in the description) which has a p38 MAP kinase inhibitory activity, a salt thereof, an N-oxide thereof, a solvate thereof, or a prodrug thereof. The compound of the invention is useful for preventing or treating a disease in which the abnormal production of a cytokine such as an inflammatory cytokine or a chemokine or overreaction to them is considered to be involved in the cause and aggravation of pathological conditions, in other words, an inflammatory disease, a respiratory disease, a cardiovascular disease, a central nervous system disease or the like, which is a cytokine-mediated disease.

Total syntheses of lyngbyabellins A and B, potent cytotoxic lipopeptides from the marine cyanobacterium Lyngbya majuscula

The first total syntheses of lyngbyabellins A and B, Lyngbya majuscula derived lipopeptides, are described. The functionalized thiazole carboxylic acid units were prepared by the oxidative dehydrogenation of the corresponding thiazolidines with chemical manganese dioxide. The asymmetric synthesis of the dichlorinated β-hydroxy acid by a chiral oxazaborolidinone mediated aldol reaction. Finally, fragment condensation followed by macrolactamization provided lyngbyabellin A. The total synthesis of lyngbyabellin B was accomplished by formation of the sensitive thiazoline ring after the macrolactamization.